Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation'

Baird analyst Brian Skorney reiterated an Outperform rating and $32.00 price target on Alto Neuroscience (NYSE: ANRO)

The analyst comments "Incrementally positive on Phase 2 CIAS initiation. Alto announced their Phase 2 trial of ALTO-101 in CIAS has begun, building on the positive tolerability profile of the transdermal formulation identified earlier this year. Alto's use of the transdermal approach allows them to achieve high drug exposure without the AEs that have dissuaded other PDE4i developers from pursuing the indication. The rapid move into a Phase 2 demonstrates Alto's clinical execution capabilities, and we expect to see a positive outcome on the primary endpoint of EEG theta band activity in 2H25."

For an analyst ratings summary and ratings history on Alto Neuroscience click here. For more ratings news on Alto Neuroscience click here.

Shares of Alto Neuroscience closed at $11.15 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker